Sequana Medical Announces the Completion of alfapump Implantations in POSEIDON, the North American Pivotal alfapump Study morningstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from morningstar.com Daily Mail and Mail on Sunday newspapers.
Reporting of primary endpoint on track for Q4 2022FDA regulatory submission on track for mid-202370% survival of POSEIDON Roll-In patients at one year post-implantation1 compares favourably
Reporting of primary endpoint on track for Q4 2022FDA regulatory submission on track for mid-202370% survival of POSEIDON Roll-In patients at one year.
Reporting of primary endpoint on track for Q4 2022FDA regulatory submission on track for mid-202370% survival of POSEIDON Roll-In patients at one year.
Positive interim analysis reported in July 2021 (https://www.sequanamedical.com/press-releases/sequana-medical-announces-positive-results-from-second-interim-analysis-of-north-american-pivotal-alfapump-study-poseidon/)Reporting